drugset / Trial / NCT00790153

To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension

NCT00790153

Phase 1 Completed 12 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

To evaluate the hormonal response to low blood sugar after a single oral dose of AZD1656 suspension.

Timeline

Start
2008-11
Primary completion
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator AZD1656 Small molecule Oral
Comparator Insulin Protein / enzyme biologic